CU6Clarity Pharmaceuticals
About Clarity Pharmaceuticals
Clarity Pharmaceuticals (ASX:CU6) is a clinical-stage radiopharmaceutical company developing next-generation theranostic (therapy and imaging) products based on its SAR Technology platform. The company's operations are focused on the development and commercialization of radiopharmaceutical products for the diagnosis and treatment of cancer. Clarity's pipeline covers large cancer indications with significant market opportunities and unmet needs, such as prostate cancer and breast cancer, as well as rare and orphan cancer indications, such as neuroblastoma.
What is CU6 known for?
Snapshot
Public AU
Ownership
2010
Year founded
43
Employees
Sydney, Australia
Head office
1 of 311
AU Rank
Unknown
Sector
N/A
Sector rank
Loading Map...
Operations
All Locations
Sydney, AU
Products and/or services of Clarity Pharmaceuticals
- Development and commercialization of radiopharmaceutical products for the diagnosis and treatment of cancer, with a focus on large cancer indications with significant market opportunities and unmet needs, such as prostate cancer and breast cancer, as well as rare and orphan cancer indications, such as neuroblastoma.
- Development of SARTATE™, a radiopharmaceutical theranostic for the diagnosis and treatment of neuroblastoma. SARTATE™ is currently in a Phase 3 clinical trial for the treatment of neuroblastoma.
- Development of SAR-bisPSMA, a radiopharmaceutical theranostic for the diagnosis and treatment of prostate cancer. SAR-bisPSMA is currently in a Phase 2 clinical trial for the treatment of prostate cancer.
- Development of SAR-Bombesin, a radiopharmaceutical theranostic for the diagnosis and treatment of neuroendocrine tumours (NETs). SAR-Bombesin is currently in a Phase 2 clinical trial for the treatment of NETs.
- Delivery of radiopharmaceutical products to patients as quickly as possible to make a significant impact on the lives of cancer patients and their families.
- Commitment to developing and commercialising innovative radiopharmaceutical products that improve the diagnosis and treatment of cancer.
Clarity Pharmaceuticals executive team
- Dr. Alan John Taylor Ph.D.Executive Chairman
- Ms. Michelle ParkerCEO, MD & Executive Director
- Mr. David K. Green BEc., CAChief Financial Officer
- Dr. Colin David Biggin Ph.D.COO & Non-Independent Executive Director
- Dr. Matthew Harris BSc., M.B.A., Ph.D.Chief Scientific Officer
- Ms. Lisa SadetskayaDirector of Corporate Communications.
- Ms. Mary BennettHead of People & Culture
- Mr. Shaemus GleasonExecutive Vice President of Operations
- Dr. Othon GervasioChief Medical Officer
- Ms. Eva LengyelovaExecutive Vice President of Clinical Development